Trials / Completed
CompletedNCT05620563
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Osteoarthritis Pain
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 147 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3857210 in participants with Osteoarthritic Pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3857210 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2022-11-22
- Primary completion
- 2023-06-05
- Completion
- 2023-06-12
- First posted
- 2022-11-17
- Last updated
- 2024-06-26
- Results posted
- 2024-06-26
Locations
30 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05620563. Inclusion in this directory is not an endorsement.